Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RADIANCE

Financiado

Cerrado

Nanoscintillators to potentiate brain cancer radiotherapy: from physics to prec...

Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trials More than 50% of cancer patients undergo radiation therapy (RT) in the course of their treatment. However, because of a lack of specificity for tumor tissues, delivering therapeutically effective doses of X rays with tolerable tox... ver más

31/12/2028

INSERM

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-12

ERC-2023-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INSERM

1.95M€ | Lider

Proyectos interesantes

EQC2019-005622-P

Medical Technol...

Nanotechnology

132K€ Cerrado

NANORADAM

Medical Technol...

Nanotechnology

100K€ Cerrado

PERSEUS

Medical Technol...

Nanotechnology

3M€ Cerrado

MAT2013-40971-R

Medical Technol...

Nanotechnology

74K€ Cerrado

NANOCANCER

Medical Technol...

Nanotechnology

158K€ Cerrado

NanoEnHanCeMent

Medical Technol...

Nanotechnology

171K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 63 meses Fecha Inicio: 2023-09-12
Fecha Fin: 2028-12-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto More than 50% of cancer patients undergo radiation therapy (RT) in the course of their treatment. However, because of a lack of specificity for tumor tissues, delivering therapeutically effective doses of X rays with tolerable toxicity on healthy tissues remains a challenge. Glioblastoma multiforme (GBM), the most common primary brain cancer in adults has a dismal prognosis despite an aggressive standard-of-care. Developing new strategies to improve the therapeutic index of RT is therefore of major importance. The aim of this project is to comprehensively study the multifaceted radiotherapeutic effect of nanoscintillators (NS), and determine how to harness these effects to improve the therapeutic index of RT. By converting high-energy photons such as X-rays into UV/visible photons, NS can augment RT by various effects. These include radiation dose enhancement, radioluminescence-induced photodynamic therapy and DNA damage generated by UV-radioluminescence. This project has three main objectives: 1) To elucidate the physical and photochemical origins of the radiotherapeutic effects of NS using spectroscopic studies to identify the reactive oxygen species and DNA lesions generated upon X-rays; 2) To study the biological impact of the NS on 3D models and in syngeneic rat models of GBM; 3) To develop an in silico program that simulates the efficacy of prospective NS, and studies the impact of their composition, size and morphology. This will tailor future NS to specific malignancies with distinct biological properties. With this innovative methodology and an interdisciplinary approach that ranges from physics to biology, this project will provide ground-breaking fundamental knowledge on the radiotherapeutic effects of NS that may lead to highly valuable and clinically translatable therapies. In the long-term, this strategy may be tailored for pancreatic and metastatic ovarian cancers, for which the multifaceted enhancement of RT efficacy by NS may be of great interest.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores